Skip to main content
Livermore
Livermore
ZHEN

Marshall Wace, LLP

SEC CIK
0001318757
Latest filing
Aug 13, 2026

ESPR holding history

Esperion Therapeutics, Inc. in every 13F filed by Marshall Wace, LLP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

ESPR overviewAll 13F holders of ESPRFull Q2 2026 holdings

Shares (Q2 2026)
14,118
Value
$44.6K
% of portfolio
<0.1%
Quarters held
19
Since Q1 2021
Holdings of ESPR by Marshall Wace, LLP, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 202614,118$44.6K<0.1%−7,060,965−99.8%ReducedHolders
Q1 20267,075,083$19.4M<0.1%+1,603,472+29.3%AddedHolders
Q4 20255,471,611$20.2M<0.1%+2,950,172+117.0%AddedHolders
Q3 20252,521,439$6.68M<0.1%−2,790,813−52.5%ReducedHolders
Q2 20255,312,252$5.21M<0.1%+1,679,294+46.2%AddedHolders
Q1 20253,632,958$5.23M<0.1%+3,632,958NewHolders
Q4 20240$00.0%−3,092,629−100.0%Sold outHolders
Q3 20243,092,629$5.10M<0.1%−1,210,967−28.1%ReducedHolders
Q2 20244,303,596$9.55M<0.1%+2,087,635+94.2%AddedHolders
Q1 20242,215,961$5.94M<0.1%+1,758,203+384.1%AddedHolders
Q4 2023457,758$1.37M<0.1%−1,116,378−70.9%ReducedHolders
Q3 20231,574,136$1.54M<0.1%+1,258,207+398.3%AddedHolders
Q2 2023315,929$439.1K<0.1%+28,324+9.8%AddedHolders
Q1 2023287,605$457.3K<0.1%+112,582+64.3%AddedHolders
Q4 2022175,023$1.09M<0.1%−385,964−68.8%ReducedHolders
Q3 2022560,987$3.76M<0.1%+534,387+2,009.0%AddedHolders
Q2 202226,600$169.0K<0.1%+26,600NewHolders
Q4 20210$00.0%−520,095−100.0%Sold outHolders
Q3 2021520,095$6.27M<0.1%−651,975−55.6%ReducedHolders
Q2 20211,172,070$24.8M0.1%+142,369+13.8%AddedHolders
Q1 20211,029,701$28.9M0.2%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.